Masako Sato

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi et al. · Breast Cancer · 2017 · 105 citations

Breast Oncology, Cancer Immunosurveillance, Death Ligand 1 +11

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab

Tomohiko Narita, Naoki Oiso, Yasunori Taketomo et al. · The Journal of Dermatology · 2015 · 51 citations

Post-bronchoscopy pneumonia in patients suffering from lung cancer: Development and validation of a risk prediction score

Hiroto Takiguchi, Naoki Hayama, Tsuyoshi Oguma et al. · Respiratory Investigation · 2017 · 25 citations

Epidemiology, Advanced Lung Disease, Patient Safety +6

High-flow nasal cannula oxygen therapy for acute exacerbation of interstitial pneumonia: A case series

Yukihiro Horio, Takahisa Takihara, Kyoko Niimi et al. · Respiratory Investigation · 2015 · 24 citations

Acute Lung Injury, Respiratory Infection, Interstitial Pneumonia +6

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami et al. · Breast Cancer · 2018 · 16 citations · Full text